Galenica Group half year results 2021

Ad hoc, Tuesday, 3 August 2021

Strong growth in first half of 2021: The Galenica Group experienced strong growth in the first half of 2021. Consolidated net sales in the first half of 2021 rose by 9.9% to CHF 1,857.1 million and adjusted EBIT increased by 21.3% to CHF 101.4 million. This despite significant declines in sales due to the absence of seasonal colds and the lack of any flu epidemic at the beginning of the year.

Highlights from the first half of 2021

  • By the end of June 2021, more than 80,000 antigen and PCR tests and over 38,000 vaccinations were performed in the pharmacies of the Galenica Group.
  • The distribution of COVID-19 self-tests as at 7 April 2021 marked the start of one of the largest distribution campaigns in the history of Swiss pharmacies.
  • The importance of pharmacies as the first point of contact for healthcare advice increased even further in the period under review due to COVID-19.
  • The logistics companies of the Galenica Group are supporting the authorities to assure COVID-19 vaccination-related logistics.
  • Verfora is strengthening its leading position in the Swiss consumer healthcare market through acquisitions and new products.
  • Thanks to the doubling of online sales of Amavita and Sun Store and the strong growth of the speciality pharmacy Mediservice, “Pharmacies at Home” (mail-order and Home Care) realised a 30.9% increase in sales.
  • New offers for specialised physicians enabled Galexis to gain further market shares.

Key figures of the Galenica Group in the first half of 2021

in CHF million

1st half year 2021

1st half year 2020

Change

Net sales

 

 

 

Products & Care segment

918.9

809.0

13.6%

-  Retail (B2C) 

834.3

729.0

14.4%

   - Local Pharmacies

616.9

563.0

9.6%

   - Pharmacies at Home

217.5

166.1

30.9%

- Professionals (B2B)

88.5

84.0

5.4%

   - Products & Brands

59.6

54.6

9.1%

   - Services for Professionals


28.9

29.4

-1.5%

Logistics & IT segment

1,377.9

1,283.4

7.4%

   - Wholesale

1,328.8

1,237.0

7.4%

   - Logistics & IT Services


50.5

48.4

4.4%

Corporate and eliminations


-439.7

-402.0


Galenica Group


1,857.1

1,690.4

9.9%

EBIT adjusted1)




Products & Care segment

76.2

61.8

23.2%

Logistics & IT segment

26.3

22.5

17.2%

Corporate and eliminations


-1.1

-0.7


Galenica Group

101.4

83.6

21.3%

Net profit adjusted1)

82.5

68.4

20.6%

1) Excluding the effects of IAS 19 and IFRS 16. Details of the adjusted key figures are explained in the half year report 2021 of the Galenica Group.

Galenica raises its guidance for 2021

Due to the strong growth and the good results of the first half year, Galenica revises its sales and EBIT guidance for the 2021 financial year: Provided that the increasing mobility of the population will not be restricted again by tighter official measures, Galenica now expects a sales growth of between 5% and 8% (previously: 3% to 5%) and an increase of the adjusted operating result (EBIT, excluding the effects of IFRS 16 and IAS 19) of between 10% and 14% (previously: 5% to 8%). Ga-lenica thereby expects that colds and seasonal flus will remain at a relatively low level in the coming autumn and winter.

Other press releases

Contact

Galenica Ltd.

Media
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 17
Mobile +41 79 371 77 24
Fax +41 58 852 85 58

Contact

Galenica Ltd.

Investors
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 29
Fax +41 58 852 85 35